UnknownPhase 2NCT00245089

Vincristine, Dactinomycin, and Cyclophosphamide in Treating Patients With Embryonal Rhabdomyosarcoma

Studying Embryonal rhabdomyosarcoma

Last synced from ClinicalTrials.gov May 8, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Japan Rhabdomyosarcoma Study Group
Principal Investigator: Hajime Hosoi
Kyoto Prefectural University of Medicine
Intervention: dactinomycin(biological)
Enrollment: 41 enrolled
Eligibility: 17 years · All sexes
Timeline: 2004

Study locations (30)

Anjo Kosei Hosptial, Anjo, Aichi-ken, Japan
Aichi Medical University, Nagakuti, Aichi-ken, Japan
National Hospital Orgnization Nagoya Medical Center, Nagoya, Aichi-ken, Japan
Ehime Prefectural Central Hospital, Matsuyama, Ehime, Japan
National Kyushu Cancer Center, Fukuoka, Fukuoka, Japan
Kurume University School of Medicine, Kurume, Fukuoka, Japan
Fukushima Medical University Hospital, Fukushima, Fukushima, Japan
Gifu Municipal Hospital, Gifu, Gifu, Japan
Gifu University Graduate School of Medicine, Gifu, Gifu, Japan
Gunma Children's Medical Center, Seta-gun, Gunma, Japan
Hiroshima University Hospital, Hiroshima, Hiroshima, Japan
National Hospital Organization - Medical Center of Kure, Kure, Hiroshima, Japan
Sapporo Medical University, Sapporo, Hokkaido, Japan
Hokkaido University Graduate School of Medicine, Sapporo, Hokkaido, Japan
Kobe City General Hospital, Kobe, Hyōgo, Japan
+15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00245089 on ClinicalTrials.gov

Other trials for Embryonal rhabdomyosarcoma

Additional recruiting or active studies for the same condition.

See all trials for Embryonal rhabdomyosarcoma →

← Back to all trials